# US 2025/0367135 A1 · Dendritic cell-mimicked nanostructure for application to cancer immunotherapy, and fabrication method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367135 A1
- Document ID: US20250367135A1
- Status: Published application
- Kind: A1
- Application number: 19/305,259
- Filed: 2025-08-20
- Published: 2025-12-04
- Earliest claimed: 2020-12-07
- Assignees: Fortuga Bio
- Applicants: Fortuga Bio
- Inventors: Jinkee HONG; Sangjun HA; Daheui CHOI; Taegun KANG; Taihyun KIM
- Web page: https://patentgrep.com/patent/US20250367135A1

## CPC

- A61K 40/24: Antigen-presenting cells [APC]
- A61P 35/00: Antineoplastic agents
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 9/5176: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}
- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 9/5192: {Processes}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/19: Dendritic cells
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- C12N 2760/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a dendritic cell-mimicked nanostructure and a fabrication method therefor and, more specifically, to a nanostructure in which a shell including a cell membrane of dendritic cell-derived lipid molecules is introduced to a nanoparticle core in order to take advantage of the surface antigen-presenting ability of dendritic cells and which enables targeting without disappearance in vivo, thereby providing an effect of inducing an effective immune response.

## Claims

### Claim 1

A fabrication method of a dendritic cell-mimicked nanostructure comprising:
purifying a cell membrane from dendritic cells;
forming a cell membrane suspension by sonicating the cell membrane;
obtaining liposomes by filtering the cell membrane suspension through a membrane filter; and
mixing nanoparticles and the liposomes and then obtaining nanoparticles into which the cell membrane has been introduced by filter extrusion.

### Claim 2 (depends on 1)

The fabrication method of the dendritic cell-mimicked nanostructure of claim 1, wherein the nanoparticles and the liposomes are mixed in a volume ratio of 1:150 to 1:300.

### Claim 3 (depends on 1)

The fabrication method of the dendritic cell-mimicked nanostructure of claim 1, further comprising:
pulsing an antigen to the nanoparticles into which the cell membrane has been introduced.

### Claim 4 (depends on 3)

The fabrication method of the dendritic cell-mimicked nanostructure of claim 3, wherein the antigen is a peptide or protein derived from a tumor antigen.

### Claim 5 (depends on 1)

The fabrication method of the dendritic cell-mimicked nanostructure of claim 1, wherein the average particle size of the liposome is 200 nm or less.

### Claim 6 (depends on 1)

The fabrication method of the dendritic cell-mimicked nanostructure of claim 1, wherein the nanoparticles into which the cell membrane is introduced have a smaller absolute value of surface potential than the nanoparticles before the cell membrane introduction.
